---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-019878"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:37:13.703682+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received deficiency letter on March 17, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
- Has 180 calendar days (until Sept 14, 2026) to regain compliance; stock continues trading on Nasdaq Global Market.
- May qualify for second 180-day compliance period on Nasdaq Capital Market if meets other listing requirements.
- Company considering options including reverse stock split; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001628280-26-019878
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828026019878/0001628280-26-019878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828026019878/skye-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-019878
- JSON: https://secwatch.observer/filing/0001628280-26-019878.json
- Plain text: https://secwatch.observer/filing/0001628280-26-019878.txt

## Source-grounded claims
- claim_id: 426aa5731bdd8027320e9a53b0f6fc40cebb8c28
  claim: Skye Bioscience, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  evidence_excerpt: March 17, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”) had been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). The Nasdaq deficiency letter has no immediate effect on the l
  evidence_url: https://www.sec.gov/Archives/edgar/data/1516551/000162828026019878/0001628280-26-019878-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.